NVO News

Anti-obesity Drugs Market Report 2026-2036: Digital Healthcare Integration Strengthens Demand with Approval Semaglutide and Tirzepatide at the Forefront of Growth

Novo Resources Releases Updated Corporate Presentation

Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average

Novo Nordisk A/S - share repurchase programme

While Other Clinics Brace for Impact, Regal Weight Loss Becomes First Texas Weight Loss Center to Embrace TrumpRx Discounts and Help Patients Save

Novo Resources Business Update

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Reset Health Further Strengthens Advisory Board With Appointment of Pinder Sahota

Nation's Largest Thyroid Cancer Center Publishes White Paper Finding No Convincing Evidence That GLP-1 Medications Cause Common Thyroid Cancers

Meijer anuncia un nuevo acceso asequible a medicamentos GLP-1 USA - español USA - English